Emergent BioSolutions Inc. (EBS) stock
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3072% below fair value
$5.89−0.15 (-2.48%)
Close on Nov 12, 2026Market cap $302.00MP/E –Yield –
Emergent BioSolutions ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Emergent BioSolutions's ebitda for the twelve months ending Sep 30, 2026 was -$91.80M, down 142.3% year over year. For fiscal 2025 it was $195.90M, up 195800.0% from the year before. Over ten years it grew 1.7% a year on average. The highest annual figure on record is $488.60M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $195.90M | +195800.0% |
| FY2024 | Dec 31, 2024 | $100.00K | – |
| FY2023 | Dec 31, 2023 | -$601.30M | – |
| FY2022 | Dec 31, 2022 | -$26.70M | -105.7% |
| FY2021 | Dec 31, 2021 | $465.20M | -4.8% |
| FY2020 | Dec 31, 2020 | $488.60M | +198.7% |
| FY2019 | Dec 31, 2019 | $163.60M | +29.7% |
| FY2018 | Dec 31, 2018 | $126.10M | -19.4% |
| FY2017 | Dec 31, 2017 | $156.50M | +17.2% |
| FY2016 | Dec 31, 2016 | $133.52M | -19.2% |
| FY2015 | Dec 31, 2015 | $165.25M | +48.2% |
| FY2014 | Dec 31, 2014 | $111.53M | +86.5% |
| FY2013 | Dec 31, 2013 | $59.81M | +45.3% |
| FY2012 | Dec 31, 2012 | $41.16M | -0.7% |
| FY2011 | Dec 31, 2011 | $41.45M | -47.9% |
| FY2010 | Dec 31, 2010 | $79.55M | +76.2% |
| FY2009 | Dec 31, 2009 | $45.15M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$20.30M | -120.3% |
| Q2 FY2026 | Jun 30, 2026 | -$101.10M | -502.8% |
| Q1 FY2026 | Mar 31, 2026 | $34.00M | -54.8% |
| Q4 FY2025 | Dec 31, 2025 | -$4.40M | -126.7% |
| Q3 FY2025 | Sep 30, 2025 | $99.90M | +9.9% |
| Q2 FY2025 | Jun 30, 2025 | $25.10M | – |
| Q1 FY2025 | Mar 31, 2025 | $75.30M | +11.2% |
| Q4 FY2024 | Dec 31, 2024 | $16.50M | – |
| Q3 FY2024 | Sep 30, 2024 | $90.90M | – |
| Q2 FY2024 | Jun 30, 2024 | -$175.00M | – |
| Q1 FY2024 | Mar 31, 2024 | $67.70M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.20M | – |
| Q3 FY2023 | Sep 30, 2023 | -$214.10M | – |
| Q2 FY2023 | Jun 30, 2023 | -$260.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$113.00M | -398.9% |
| Q4 FY2022 | Dec 31, 2022 | -$19.60M | -106.2% |
| Q3 FY2022 | Sep 30, 2022 | -$13.10M | – |
| Q2 FY2022 | Jun 30, 2022 | -$31.80M | -178.9% |
| Q1 FY2022 | Mar 31, 2022 | $37.80M | -68.7% |
| Q4 FY2021 | Dec 31, 2021 | $316.00M | +42.0% |
| Q3 FY2021 | Sep 30, 2021 | -$12.00M | -113.3% |
| Q2 FY2021 | Jun 30, 2021 | $40.30M | -73.9% |
| Q1 FY2021 | Mar 31, 2021 | $120.90M | +628.3% |
| Q4 FY2020 | Dec 31, 2020 | $222.60M | +400.2% |
| Q3 FY2020 | Sep 30, 2020 | $90.10M | -8.4% |
| Q2 FY2020 | Jun 30, 2020 | $154.60M | +619.1% |
| Q1 FY2020 | Mar 31, 2020 | $16.60M | – |
| Q4 FY2019 | Dec 31, 2019 | $44.50M | +327.9% |
| Q3 FY2019 | Sep 30, 2019 | $98.40M | +192.0% |
| Q2 FY2019 | Jun 30, 2019 | $21.50M | -72.9% |
| Q1 FY2019 | Mar 31, 2019 | -$800.00K | -128.6% |
| Q4 FY2018 | Dec 31, 2018 | $10.40M | -81.2% |
| Q3 FY2018 | Sep 30, 2018 | $33.70M | -41.5% |
| Q2 FY2018 | Jun 30, 2018 | $79.20M | +329.0% |
| Q1 FY2018 | Mar 31, 2018 | $2.80M | -88.8% |
| Q4 FY2017 | Dec 31, 2017 | $55.39M | +9.1% |
| Q3 FY2017 | Sep 30, 2017 | $57.57M | – |
| Q2 FY2017 | Jun 30, 2017 | $18.46M | – |
| Q1 FY2017 | Mar 31, 2017 | $25.08M | – |
| Q4 FY2016 | Dec 31, 2016 | $50.78M | – |
See a number that looks wrong?